vers la météo de la validation par utilisateur
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+SUBJ:V-N+---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,__SP__) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +---------SUBJ:V-N---------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) SUBJ:V-N (exhibit,cell) OBJ:V-N (exhibit,hyperinsulinemia) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +---OBJ:V-N---+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) OBJ:V-N (exhibit,hyperinsulinemia) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,exhibit) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-----------------------------------------SUBJ:V-N----------------------------------------+ +-------------COMP:N-N(from)-------------+ | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ +-------------COMP:N-N(from)-------------+ +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,hyperinsulinemia) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+ | | +-----------------------------------------SUBJ:V-N----------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | +--------MOD_ATT:N-ADJ--------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-ADJ----+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | | +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (hyperinsulinemia,obese) MOD_ATT:N-ADJ (hyperinsulinemia,__SP__) MOD_ATT:N-N (hyperinsulinemia,exhibit) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,hyperinsulinemia) SUBJ:V-N (decrease,administration) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +--COMP:N-N(from)-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,__SP__) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | | +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ +MOD_AT+ +-MOD_ATT:N-N-+ +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (__SP__,obese) MOD_ATT:N-N (hyperinsulinemia,exhibit) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,__SP__) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ +---------------------------COMP:V-N(after)---------------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)---------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:V-N(after) (decrease,treatment) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +------------------------APPOS------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ | +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (__NODE__,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +--------------------------------APPOS-------------------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) APPOS (administration,period) OBJ:V-N (with,mg/day) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +----------------------COMP:N-N(after)---------------------+ | | | | +-----------COMP:N-N(of)----------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) COMP:N-N(of) (mg/day,week) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ +------COMP:N-N(from)------+ | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) COMP:N-N(from) (cell,exhibit) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+--------COMP:N-N(after)-------+ +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) COMP:N-N(after) (protein,treatment) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-ADJ (treatment,initial)
+-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+ | +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +----------------------COMP:N-N(after)---------------------+ | | | +-------------------OBJ:V-N------------------+ | +--------COMP:N-N(of)-------+ | | +-MOD_ATT:N-ADJ-+ +---------APPOS--------+ +-------OBJ:V-N-------+ +COMP:N-N(o+ | | +-MOD_ATT:N-ADJ-+ | +MOD_ATT:+ | +MOD_ATT:+ | +MOD_ATT:N+-COMP:N-N(of)-+ | +COMP:N-+ | +MOD_ATT:+ +MOD+ +--OBJ:V-N-+ | +MOD_ATT+ +MOD+MOD:A+ +MOD_ATT:+ | | | | | | | | | | | | | | | | | | | | | | | | | | | In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 4 weeks after initial treatment . MOD_ATT:N-ADJ (cell,mononuclear) MOD_ATT:N-ADJ (exhibit,obese) MOD_ATT:N-ADJ (exhibit,__SP__) APPOS (hyperinsulinemia,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,__NODE__) OBJ:V-N (with,mg/day) OBJ:V-N (with,period) COMP:N-N(of) (dosage,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,week) MOD_ATT:N-ADJ (week,4) COMP:V-N(In) (decrease,cell) COMP:V-N(from) (decrease,exhibit) SUBJ:V-N (decrease,hyperinsulinemia) OBJ:V-N (decrease,expression) COMP:N-N(of) (expression,protein) COMP:N-N(after) (expression,treatment) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) MOD_ATT:N-ADJ (week,4) MOD:ADV-N (after,week) MOD_ATT:N-N (treatment,initial)
